The effect of insulin-like growth factor I (IGF-I) on growth of small cell lung cancer (SCLC) cell lines was studied. Western blot analysis of whole cell lysates of cell lines NCI-H345 and NCI-N417 demonstrated the presence of a 16-kD band consistent with an IGF-I precursor molecule. Scatchard plot analysis of cell line NCI-H345 using '25I-labeled IGF
Introduction
The ability of cancer cells to produce and respond to their own growth factors (autocrine secretion) may be a central mechanism in the process of malignant proliferation (1) . The prolif-eration of human small cell lung cancer (SCLC)' cells in response to the autocrine secretion of the neuropeptide, gastrinreleasing peptide (GRP), can be blocked in vitro and in vivo using an anti-GRP MAb (2) . The disruption of autocrine secretion ofGRP is the basis for a new therapeutic approach that is being evaluated in a clinical trial. SCLC is known to produce a wide variety ofpeptide hormones (3) , and the proliferation of SCLC might also depend on others of its own peptide hormone products (4) . If other growth factors for SCLC function through an autocrine-type mechanism, they could provide additional targets for the therapeutic control of SCLC proliferation.
An obvious candidate to evaluate for such autocrine activity is insulin-like growth factor-I (IGF-I), which is a mitogen for many types of cells both in vitro and in vivo (5, 6) . Several investigators have shown that IGF-I or IGF-I-like peptides are produced and/or released by cultured human tumor cell lines (7) (8) (9) of fresh human tumor specimens including some lung cancers (10, 1 1). IGF-I-like peptides have also been implicated as autocrine/paracrine growth factors in human breast cancer (12) .
Insulin and IGF-I are peptides that are closely related in their primary structures (13) and biological activities (5) . Each hormone binds to its own receptor with high affinity and to the other's with lesser affinity (14, 15) . Insulin has been found to be one of the potent growth stimulators for SCLC (16) , although supraphysiological concentrations of insulin were required for optimal proliferation. In a survey of peptide hormone secretion, insulin was detected in < 10% of SCLC cell lines (17) . King et al. reported that the mitogenic effect of insulin for human fibroblast was not mediated by the insulin receptor, since this effect was not inhibited by polyclonal anti-insulin receptor antibodies known to block ligand binding to the insulin receptor (18) . Later studies revealed that the mitogenic effect of insulin on human fibroblasts was mediated by the IGF-I receptor, since a mouse MAb that specifically binds to the IGF-I receptor, aIR3 (19) , blocks the mitogenic effects of both IGF-I and insulin in human fibroblasts (20, 21) . IGF-II, another related member of the IGF family, mediates many of the same effects as IGF-I (22, 23) . IGF-II binds with lesser affinity to the IGF-I receptor and therefore is less potent in stimulating biological events mediated by that receptor.
1. Abbreviations used in this paper: GRP, gastrin-releasing peptide; IGF, insulin-like growth factor; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide; R-S, RPMI and/or insulin. At the end of the incubation period, free ligand was separated from the membrane-bound ligand by filtration under reduced pressure using a disposable manifold (V & P Scientific, San Diego, CA). The filters were pretreated with 0.01% poly-L-lysine + 1% BSA in 50 nM Tris-HCI, pH 7.6. After being washed three times with buffer, the filters were counted in a gamma counter (Micromedic Systems, Inc., Horsham, PA). Specific binding was calculated as the difference between total binding and binding in the presence ofthe unlabeled ligand. Membrane protein concentrations were determined using the Bio-Rad (Bio-Rad Laboratories, Richmond, CA) protein assay kit. Data for the competition binding studies were analyzed using a computer-assisted linear regression analysis.
MiT assays. The semiautomated colorimetric assay (MTT assay) is based on the ability ofcells to reduce a tetrazolium-based compound (MTT) (30, 31) . Under defined conditions, the cell number is directly proportional to MTT reduction (31), so for the experiments reported here, a doubling ofoptical density indicated a doubling ofcell number. Cells were harvested and washed three times in RPMI 1640 medium. An aliquot of0.1 ml cell suspension was plated in 96-well tissue culture plates (Costar, Data Packaging Corp., Cambridge, MA). The growth factor solutions (0.1 ml) with/without antibodies in serum-free basal media, which consisted of RPMI 1640 medium plus a final concentration of 10 ug/ml transferrin and 300 nM selenium (Rns), were added in each well. Assay conditions were established so that the tumor cells maintained constant growth in RTs in excess of the time period analyzed in these experiments. After 7 d incubation, 0.1 mg (0.05 ml of 2 mg/ml) MTT was added and the plates were incubated at 370C for 4 h. The plates then were centrifuged at 150 g for 5 min and the media were removed. The crystalline-reduced MTT product was solubilized in 0.18 ml DMSO and absorbance was measured using an automated microplate reader (Bio-Tek Instruments, Inc., Burlington, VT) at dual wavelengths of 540 and 690 nm.
Results
Western blot analysis. A variant SCLC line, NCI-N4 17, and a classic SCLC cell line, NCI-H345, were analyzed for the expression ofIGF-I precursor molecules by Western blot analysis as shown in Fig. 1 . A 16-kD band was evident in both cell types using the rabbit anti-IGF-I immune sera. This reactivity was lost ifthe antisera were preincubated with a 10-,MM solution of synthetic IGF-I. These data suggest that both types of SCLC cell lines produce a molecule whose immunologic characteristics and molecular weight are consistent with the previously reported IGF-I precursor molecule (22) .
Receptor assays. Using '251-IGF-I, the cell line NCI-H345 was shown to contain specific binding sites for IGF-I that were saturable with respect to the radiolabeled ligand concentration. Scatchard plots (not shown) of the radiolabeled ligand binding could be resolved into two linear components Growth-stimulating effect ofexogenous insulin, IGF-I, and IGF-II. Growth of the SCLC cells in various concentrations of IGF-I and IGF-II (1 pg/ml to 1 ug/ml) or insulin (1 ng/ml to 1 mg/ml) was compared with that in basal RTs media not containing these factors. A representative dose response curve for one cell line, NCI-H82, is shown in Fig. 2 . The data for the cell lines at the optimal concentration of the peptides are summarized in Table I . The optimal concentration of IGF-I (0.1-1 ,ug/ml) was 10-100-fold less than that of insulin (10-100 Ag/ml) or IGF-II (1 ug/ml) for all the cell lines. The maximum cell growth for an individual cell line resulting from the addition of optimal concentration of any of the peptides was almost identical. As shown in Table I , the responsiveness to exogenous addition of IGF-I or insulin varied between the individual SCLC cell lines. For the low responder, NCI-N4 17, Fig. 3 . The MAb, aIR-3, inhibited both IGF-I-and insulin-mediated growth of all four SCLC cell lines tested in a dose-dependent fashion as shown in Table II . High concentrations (10 Ag/ml) of aIR-3 almost completely blocked the IGF-I-and insulin-mediated cell growth of the four cell lines (16.3 to -147% of maximum growth). The same concentration of the isotypic control antibody (MOPC-2 1) had minimal inhibitory effect. The cell line with the least amount of growth in response to exogenous IGF-I or insulin (NCI-N4 17) had the most marked response to aIR-3 exposure (-147.5 and -122.8% maximum growth), suggesting that at least in this cell line we were seeing antibody inhibition of endogenous IGF-I activity. To test for this, we next evaluated the effect of aIR3 on growth of the SCLC cell lines grown precisely as before, although now in the absence of insulin or IGF-I (RTrs). In four separate experiments, the highest concentration of aIR3 (10 ,g/ml) mediated growth inhibition for all four cell lines: with a mean of 28% for NCI-N4 17, 26% for NCI-H82, 22% for NCI-H345, and 21% for NCI-H209 compared with growth of cells in RTS alone. Lesser degrees of inhibition were seen at the lower doses of aIR3 (0.1, 1 ,ug/ml), and no inhibition was seen at any of the three concentration (0.1, 10 jig/ml) for an isotypic control antibody, MOPC-21
(data not shown).
Discussion
Both classic (NCI-H345) and variant (NCI-N417) SCLC lines produce a molecule of the appropriate weight and immuno- logic specificities to be consistent with an IGF-I precursor (22) . We have previously reported that dot blot analysis of spent conditioned media from NCI-H345 revealed a molecule that was immunologically cross-reactive with IGF-I (32). Receptor assays demonstrate two classes ofbinding sites that are present on NCI-H345 consistent with previous characterization of the IGF-I receptor (29, 33) . Insulin competition experiments confirmed that the binding to the high affinity site was specific for the IGF-I receptor as previously demonstrated (29) . The cell growth experiments have demonstrated that IGF-I and insulin significantly stimulate the growth of four SCLC cell lines. The maximum growth of each SCLC cell line after the exogenous addition of IGF-I, IGF-II, or insulin is similar, but consistently occurs at a 10-100-fold lesser concentration for IGF-I. This situation has been previously reported with other cells in vitro (15, 23) and suggests stimulation is mediated by the IGF-I receptor.
The MAb to the IGF-I receptor inhibits both IGF-I and insulin-mediated growth stimulation of human SCLC cell lines in a dose-dependent manner, as shown in Fig. 2 and Table II (IGF-II stimulation was also blocked in a similar fashion by aIR-3, data not shown). These experiments also suggest that the mitogenic effects of IGF-I, IGF-II, and insulin on human SCLC cell lines are predominantly mediated through the IGF-I receptor, as has been previously described in experiments comparing the effect of aIR-3 on IGF-I-and insulinmediated growth of cultured human fibroblasts in serum-free media (20, 21) . The sensitivity of the SCLC cell lines to exogenous addition of both IGF-I and insulin is varied (Table I) . lp the four SCLC cell lines tested, the degree of growth inhibition by a high concentration (10 gg/ml) of aIR-3 is inversely rplated to the sensitivity to exogenous insulin and IGF-I, i.e., the lowest responder to these growth factors, NCI-N417, is the most sensitive to the effect of aIR-3. These results suggest interference of IGF-I-receptor-mediated mitogene~is of both exogenous and endogenous IGF-I activity on SCLC cell lines. Similar experiments conducted in the absence of exogenous IGFs or insulin confirm that the anti-IGF-I receptor antibody inhibits cell growth below baseline, which suggests an auto-stimulatory role for an IGF-I-like activity for all four cell lines. The degree of inhibition of growth caused by the anti-IGF-I receptor antibody in basal media (i.e., insulin-or IGF-I-free RTS) was not as marked as that seen when we evaluated the effect of aIR-3 on exogenous IGF-I or insulin. The greater cell growth in the control plates for the cells grown in RTIS (RTS with insulin added) or (RTSIGF-I [RTS with IGF-I added]) compared with those in RTs, has a major effect on the calculation of the percent inhibition of growth. Since FCS generally contains significant and variable amounts of IGF-I and other growth factors, it was avoided in these experiments, as with other experiments evaluating growth factor effects (3, 4, 20) to ensure reproducibility of these results.
In considering the results of the receptor experiments, the effect of endogenous IGF-I activity on radiolabeled ligand binding can not be fully assessed. Endogenous production of an IGF-I molecule may lead to an underestimate ofthe KD and Bmax of the ligand for the IGF-I receptor due receptor occupancy, though this effect is hard to quantitate in this system. All four cell lines tested respond to exogenous peptide and show growth inhibition in basal conditions after exposure to an anti-IGF-I receptor MAb. Our limited receptor binding analysis suggests that for at least NCI-H345, the binding charactenrstics of the IGF-I receptor are similar to the previously characterized IGF-I receptors (29, 33) .
We have shown evidence for peptide production, high affinity receptors, and in vitro growth stimulation of IGF-I for SCLC cell lines. The MAb to the IGF-I receptor (aIR-3) also successfully inhibits the IGF-I-and insulin-(and IGF-II) mediated proliferation of SCLC. IGF-I is more potent on a molar basis than either insulin or IGF-II in stimulating SCLC growth. In light of those findings, the experiments with the antibody to the IGF-I receptor performed in basal media (insulin-or IGF-free) suggest that IGF-I or a very closely related entity can function as an autocrine growth factor for SCLC. We have previously demonstrated that GRP (2) and recently a transferrin-like molecule (31, 34) may share this role in SCLC. This is the first example of a solid tumor that is potentially responsive to multiple autocrine factors, and as such provides an unique model for further study of this complex system to ultimately facilitate understanding of the regulation of proliferation in this lethal malignancy.
